COVID-19 Vaccination for Frail Older Adults in Singapore — Rapid Evidence Summary and Delphi Consensus Statements - 21/11/24

Doi : 10.14283/jfa.2022.12 
J. Gao 1, P. Lun 1, Y.Y. Ding 1, 2, Pradeep Paul George 1, 3, 4, 5,
1 Geriatric Education and Research Institute, Singapore, Singapore 
2 Department of Geriatric Medicine, Tan Tock Seng Hospital, Singapore, Singapore 
3 Health Services and Outcomes Research, National Healthcare Group, Singapore, Singapore 
4 Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore 
5 Faculty of Health Sciences, University of Adelaide, Adelaide, Australia 

d pradeep_paul_g_gunapal@nhg.com.sg pradeep_paul_g_gunapal@nhg.com.sg

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

Objective

This study aimed to synthesize available evidence on the effectiveness and safety of COVID-19 vaccines for frail older adults through a rapid review, supplemented with geriatricians’ consensus statements.

Methods

References were identified through MEDLINE and Web of Science on 1st February 2021 using relevant terms related to COVID-19, vaccine, and older adults. Searches were also conducted on reference lists of review articles and Google Scholar. The content was updated on 8th April via hand searching. We included studies on Phase III randomized controlled trials, and data from real world administration of vaccines. A two-round Delphi study was conducted with 15 geriatricians to elicit their thoughts and recommendations regarding COVID-19 vaccination for frail older adults.

Results

Five Phase III randomized controlled efficacy trials reported vaccine efficacy ranging from 66.7% to 95% among participants aged 16 to 95. The vaccine efficacy for participants aged 65 and above is 94.7% and 86.4% for Pfizer-BioNTech and Moderna respectively. Sputnik V reported a vaccine efficacy of 91.8% for participants 60 and above. Serious adverse events were reported by 0.27% to 1% of participants who received at least one dose of the four vaccines. For the Delphi study, 16 out of 24 statements achieved consensus. The Delphi panel opined that frail or very old adults, except those with limited life expectancy, should be vaccinated due to their vulnerability. They also agree that vaccination decisions should be made by patients when possible, with the involvement of next-of-kin should the frail older adult be unable to do so. Lastly, the panel thought that frail older adults should be included in future clinical trials.

Conclusion

In early clinical trials, there is paucity of evidence on efficacy and safety of current COVID-19 vaccines among frail older adults. Geriatricians’ consensus indicate that frail older adults should be vaccinated except where life expectancy is limited. Future trials assessing efficacy and safety should include frail older adults.

Le texte complet de cet article est disponible en PDF.

Key words : COVID-19, vaccine, frail, older adults, elderly


Plan


 Electronic Supplementary Material
Supplementary material is available for this article at jfa.2022.12 and is accessible for authorized users.


© 2022  THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 11 - N° 2

P. 236-241 - avril 2022 Retour au numéro
Article précédent Article précédent
  • Social Detachment Influenced Muscle Mass and Strength during the COVID-19 Pandemic in Japanese Community-Dwelling Older Women
  • B.K. Son, T. Imoto, T. Inoue, T. Nishimura, T. Tanaka, K. Iijima
| Article suivant Article suivant
  • Frailty Status and Outcomes of COVID-19 Patients Admitted to an Intensive Care Unit
  • Matthew Rhys Jones, C.P. Subbe, C. Thorpe, C. Pickwick

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.